retatrutide parkinson's disease trial nct 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN CLINICAL TRIALS, is showing incredible results, with some Parkinson's Disease Drug Therapies in

36 Finally, a cross-sectional study also demonstrated adverse effects of GLP-1 agonists, with patients on exenatide reporting higher PHQ-9 scores (9.70 4.92 vs 6.70 4.66

GLP-1 drugs, on the other hand, have seen explosive growth

July 22, 2025 - Let'sGetChecked In-Home Kit Mailing We continue to partner with LetsGetChecked to mail FOBT and/or a combination A1c/kidney health evaluation kit to Medicare Advantage members who are non-compliant with their colorectal cancer screening and/or diabetes management test

Semaglutide (once weekly

I would not recommend microdosing GLP-1s for individuals with significant amounts of weight to lose or known metabolic dysregulation. The bottom line is that there are still questions regarding the effectiveness and safety of microdosing GLP-1 medications, and this type of regimen is not for everyone

Risk monitoring will also help companies plan for critical suppliers such as reagents